The FDA is hosting a virtual public workshop on September 19, 2022 on "Increasing the Efficiency of Biosimilar Development Programs." The workshop will focus on comparative clinical studies and "discuss possible innovative ideas to improve the efficiency of biosimilar development." The workshop will include detailed discussion on the statistical methods for these studies, e.g., the Bayesian integration of various data sources to inform the design of the comparative clinical study. Additional discussions will focus on other clinical study design elements and recommendations to help increase the efficiency of these studies, such as the selection of endpoints. The workshop is open to the public, but registration is required. Further information, including how to register, is provided on the FDA site.
FDA Workshop On Sept. 19, 2022: Increasing The Efficiency Of Biosimilar Development Programs
Goodwin Procter LLP
Contributor
At Goodwin, we partner with our clients to practice law with integrity, ingenuity, agility, and ambition. Our 1,600 lawyers across the United States, Europe, and Asia excel at complex transactions, high-stakes litigation and world-class advisory services in the technology, life sciences, real estate, private equity, and financial industries. Our unique combination of deep experience serving both the innovators and investors in a rapidly changing, technology-driven economy sets us apart.
The FDA is hosting a virtual public workshop on September 19, 2022 on “Increasing the Efficiency of Biosimilar Development Programs...